Risks

High net debt to EBITDA and zero interest coverage leave KRMD more exposed than larger peers to refinancing pressure if growth or margins soften, constraining strategic flexibility.

A 83-day cash conversion cycle, driven by 96 days of inventory, ties up working capital more than asset-light medtech peers and can pressure liquidity during demand volatility.

KRMD’s current and quick ratios are solid, but its smaller scale versus diversified competitors leaves less buffer if payer mix, reimbursement, or demand conditions deteriorate.

Inventory-heavy operations increase obsolescence and write-down risk relative to peers with shorter supply chains, which can compress margins if product demand shifts unexpectedly.

Opportunities

KRMD’s liquidity ratios above 2.0 provide more near-term operating flexibility than leveraged small-cap peers, supporting execution if demand and reimbursement remain stable.

The company’s niche plasma-derived therapy focus can benefit from structurally resilient demand versus broader medtech peers, where elective procedure exposure is more cyclical.

If working-capital discipline improves, the long cash conversion cycle offers meaningful upside to cash generation relative to peers with already optimized inventory turns.

Lower debt-to-equity than many leveraged healthcare peers reduces balance-sheet drag, giving KRMD more room to absorb growth investments without immediate dilution pressure.

Overall Score

KRMD’s forward positioning is balanced by solid near-term liquidity and niche demand support, but elevated leverage, weak interest coverage, and working-capital intensity limit peer-relative upside.